Loblaw Companies Limited · TSX:L
Loblaw Companies — Q1 2015 Earnings Presentation
9 slides from Loblaw Companies's earnings presentation, May 6, 2015
Slide 1: Q1 2015 Supplementary Slides
Q1 2015 Supplementary Slides May 6, 2015 1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation for Loblaw Companies Limited (“Loblaw” or “the Company”) contains forward-looking statements about the Company’s objectives, plans, goals, aspirations, strategies, financial condition, results of operations, cash flows, performance, prospects and opportun
Slide 3: Key Financial Metrics – Loblaw – Q1 2015
Key Financial Metrics – Loblaw – Q1 2015 Consolidated Revenue $10,048M, +37.8% (+2.2% ex. Shoppers Drug Mart) Adjusted EBITDA $789M, +63.7% Adjusted Operating Income $543M, +89.2% Adjusted EPS $0.73, +35.2% Net Efficiencies Achieved (ex SDM) Efficiencies in Admin, IT and Supply Chain Net Synergies $
Slide 4: Key Retail Metrics – Q1 2015
Key Retail Metrics – Q1 2015 Retail Revenue $9,830, +38.5% Retail Revenue – Loblaw $7,234M, +2.0% Retail Revenue – SDM $2,596M, +3.1% Retail Adjusted Gross Profit and Margin $2,624 (+63.7%); 26.7% (410bps) Retail Adjusted Gross Profit – Loblaw $1,633, +1.9% Excluding the impact of changes to franchi
Slide 5: Key Operational Metrics – Q1 2015 – Loblaw
Key Operational Metrics–Q1 2015—Loblaw +4.0% (ex Gas Bar (120bps) and the negative impact of a Same Store Sales Food Retail change in the distribution model by a tobacco supplier (80bps); including these items food retail comp SSS was +2.0%) Basket Size Increased Traffic Increased Internal Inflation
Slide 6: Key Operational Metrics – Q1 2015 Shoppers Drug Mart
Key Operational Metrics – Q1 2015 Shoppers Drug Mart Revenue $2,596, +3.1% Retail Selling Square Footage Growth +0.5% vs. Q1 2014 Pharmacy Sales $1,257M, +3.6% Pharmacy SSS +3.5% # Rx Dispensed (Rx Count) +4.8% (+4.7% on same store sales basis) Average Rx Value -1.1% Generic Penetration 64.5% (vs. 6
Slide 7: Shoppers Drug Mart – Q1 2014 Highlights
Shoppers Drug Mart – Q1 2014 Highlights $ Millions Sales $2,518 Gross Profit $966 Adjusted Operating Income $179 Adjusted EBITDA $239 Note: The above earnings were initially released as part of ‘Addendum B’ in the Q2, 2014 press release announced July 24, 2014 Pharmacy Sales +0.5% Pharmacy SSS +0.4%
Slide 8: Adjusted Debt by Segment
Adjusted Debt by Segment $ Millions Q1 2015 Retail PCF REIT Con. & Elim. Bank Indebtedness $ 299 $ 299 $ - $ - $ - Short term debt 505 - 505 ‐ ‐ Long term debt due within one year 445 53 392 ‐ - Long term debt 10,922 7,127 993 7,146 (4,344) Trust Unit Liability 784 - - - 784 Capital securities 225 2
Slide 9: Adjusted Debt
Adjusted Debt Adjusted Debt at Acquisition $11,060 $1.5B Choice Properties REIT Monetization 1,500 Repayment of Term Loan (2,271) ($1,065) 4.85% MTN Matured and Repaid (350) Other 56 Year End 2014 Reported Adjusted Debt $9,995 $207M Repayment of Term Loan (207) $122M Repayment of REIT Cr